Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study
CONCLUSION: We found that the risk of bleeding in patients taking Crude low molecular weight heparins was significantly higher compared to other antithrombotic agents, but with a small magnificence, which may be attributed to the severely irrational use of this medication under improper management. Statistics in days, results showed that the risk of bleeding decreased over time for warfarin and clopidogrel and increased for alteplase, nadroparin, and dipyridamole.PMID:38497691 | DOI:10.1080/14740338.2024.2327502 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 18, 2024 Category: Drugs & Pharmacology Authors: Kangyuan Guo Ganyi Wang Li Zhang Zhanchun Feng Xudong Xia Xiaobo Sun Ziqi Yan Zhiming Jiao Da Feng Source Type: research
Characteristics and outcomes in elderly patients with non-valvular atrial fibrillation and high bleeding risk: subanalysis of the J-RHYTHM Registry
AbstractRecently, a once-daily dose of edoxaban (15-mg) has been approved for stroke prevention in non-valvular atrial fibrillation (NVAF) patients aged ≥ 80 years, in whom standard oral anticoagulants are not recommended because of high bleeding risk (HBR), based on the ELDERCARE-AF trial. However, information regarding the characteristics and clinical outcomes among such patients is limited. Thus, this study aimed to clarify the characteri stics and event rates in elderly patients with NVAF and HBR defined by the ELDERCARE-AF criteria. Of the 7406 NVAF outpatients included in the J-RHYTHM Registry, 60 patients wi...
Source: Heart and Vessels - March 16, 2024 Category: Cardiology Source Type: research
A physiologically ‐based pharmacokinetic/pharmacodynamic modeling approach for drug–drug‐gene interaction evaluation of S‐warfarin with fluconazole
This study provides a whole-body physiologically-based pharmacokinetic/PD (PBPK/PD) model of S-warfarin for predicting the effects of drug–drug−gene interactions on S-warfarin PKs and PDs. The PBPK/PD model of S-warfarin was developed in PK-Sim and MoBi. Drug-depende nt parameters were obtained from the literature or optimized. Of the 34 S-warfarin plasma concentration-time profiles used, 96% predicted plasma concentrations within twofold range compared to observed data. For S-warfarin plasma concentration-time profiles withCYP2C9 genotype, 364 of 386 predicted plasma concentration values (~94%) fell within the twofold...
Source: CPT: Pharmacometrics and Systems Pharmacology - March 15, 2024 Category: Drugs & Pharmacology Authors: Kuo Geng,
Chaozhuang Shen,
Xiaohu Wang,
Xingwen Wang,
Wenxin Shao,
Wenhui Wang,
Tao Chen,
Hua Sun,
Haitang Xie Tags: ARTICLE Source Type: research
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects
ConclusionsDaridorexant at 50 mg is classified as a weak CYP3A4 inhibitor after single- and multiple-dose administration once daily at steady state. Daridorexant 50 mg did not induce CYP3A4 activity or inhibit CYP2C9 activity.Clinical Trial RegistrationThis trial (NCT05480488) was registered on 29 July, 2022. (Source: Drugs in R&D)
Source: Drugs in R&D - March 13, 2024 Category: Drugs & Pharmacology Source Type: research
Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa
This study assessed the quality of anticoagulation and associated factors among VKA-treated patients in nine SSA countries. We conducted a retrospective cohort study of randomly selected patients on anticoagulation from 20 clinics in Botswana, the Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Tanzania, and South Africa. Eligible participants were those on VKAs for at least three months and with at least four international normalised ratios (INR) results in 2019 –2021. We report the proportion of INR values in the therapeutic range, time-in-therapeutic range (TTR) using the Rosendaal method, ...
Source: Journal of Thrombosis and Thrombolysis - March 13, 2024 Category: Hematology Source Type: research
Half-dose direct oral anticoagulation versus warfarin for atrial fibrillation following cardiac surgery
CONCLUSIONS: In comparison to warfarin, half-dose DOAC anticoagulation in patients with atrial fibrillation following cardiac surgery is associated with a shorter postoperative length of stay, without a significant increase in stroke/transient ischemic attack, reoperation for bleeding or postoperative blood product transfusion. Follow-up echocardiography in anticoagulated patients is recommended to rule out significant sanguineous pericardial effusions in the early postoperative period following hospital discharge.PMID:38470020 | DOI:10.23736/S0021-9509.24.12815-7 (Source: The Journal of Cardiovascular Surgery)
Source: The Journal of Cardiovascular Surgery - March 12, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Sabet W Hashim Susan Collazo Amanda Greco Jeff F Mather Raymond G McKay Source Type: research
Half-dose direct oral anticoagulation versus warfarin for atrial fibrillation following cardiac surgery
CONCLUSIONS: In comparison to warfarin, half-dose DOAC anticoagulation in patients with atrial fibrillation following cardiac surgery is associated with a shorter postoperative length of stay, without a significant increase in stroke/transient ischemic attack, reoperation for bleeding or postoperative blood product transfusion. Follow-up echocardiography in anticoagulated patients is recommended to rule out significant sanguineous pericardial effusions in the early postoperative period following hospital discharge.PMID:38470020 | DOI:10.23736/S0021-9509.24.12815-7 (Source: The Journal of Cardiovascular Surgery)
Source: The Journal of Cardiovascular Surgery - March 12, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Sabet W Hashim Susan Collazo Amanda Greco Jeff F Mather Raymond G McKay Source Type: research
Half-dose direct oral anticoagulation versus warfarin for atrial fibrillation following cardiac surgery
CONCLUSIONS: In comparison to warfarin, half-dose DOAC anticoagulation in patients with atrial fibrillation following cardiac surgery is associated with a shorter postoperative length of stay, without a significant increase in stroke/transient ischemic attack, reoperation for bleeding or postoperative blood product transfusion. Follow-up echocardiography in anticoagulated patients is recommended to rule out significant sanguineous pericardial effusions in the early postoperative period following hospital discharge.PMID:38470020 | DOI:10.23736/S0021-9509.24.12815-7 (Source: The Journal of Cardiovascular Surgery)
Source: The Journal of Cardiovascular Surgery - March 12, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Sabet W Hashim Susan Collazo Amanda Greco Jeff F Mather Raymond G McKay Source Type: research
Safety Issues of Herb-Warfarin Interactions
Curr Drug Metab. 2024 Mar 8. doi: 10.2174/0113892002290846240228061506. Online ahead of print.ABSTRACTWarfarin is a popular anticoagulant with high global demand. However, studies have underlined serious safety issues when warfarin is consumed concomitantly with herbs or its formulations. This review aimed to highlight the mechanisms behind herb-warfarin interactions while laying special emphasis on its PKPD interactions and evidence on Herb-Warfarin Interaction (HWI) with regards to three different scenarios, such as when warfarin is consumed with herbs taken as foods or prescribed as medicine, or when used in special sit...
Source: Current Drug Metabolism - March 11, 2024 Category: Drugs & Pharmacology Authors: Subhajit Hazra Preet Amol Singh Neha Bajwa Source Type: research
Evaluation of the Safety of Uninterrupted Warfarin Anticoagulation With Tranexamic Acid in Total Joint Arthroplasty
CONCLUSION: Many factors must be considered when choosing perioperative thromboembolic prophylaxis for arthroplasty candidates with medical comorbidities requiring long-term anticoagulation. This study presents data indicating that it could be safe and effective to continue therapeutic warfarin while using prophylactic TXA. [Orthopedics. 202x;4x(x):xx-xx.].PMID:38466825 | DOI:10.3928/01477447-20240304-04 (Source: Orthopedics)
Source: Orthopedics - March 11, 2024 Category: Orthopaedics Authors: Michael G Johnston Matthew A Porter Kade E Eppich Celeste G Gray David F Scott Source Type: research
